Table 1.
Clinical characteristics of cohorts 1 and 2.
| Variable | Number (%) | |
|---|---|---|
| All Patients | Cohort 1 67 (100%) |
Cohort 2 42 (100%) |
| Tumor type (histology) | ||
| -Non seminoma | 54 (80.3) | 31 (73.8) |
| Embryonal carcinoma $ | 44 | 19 |
| Choriocarcinoma | 6 | 9 |
| Yolk sac | 23 | 17 |
| Teratoma | 26 | 25 |
| Seminoma | 30 | 17 |
| -Pure Seminoma | 13 (19.7) | 10 (23.8) |
| -Extragonadal | 1 (2.4) | |
| IGCCCG Risk Group | ||
| -Good | 56 (83.6) | 11 (26.2) |
| -Intermediate | 10 (14.9) | 15 (35.7) |
| -Poor | 1 (1.5) | 16 (38.1) |
| Response to Chemotherapy | ||
| -Durable complete response (NED) | 60 (89.5) | - |
| -Relapse after complete response (NED) | 6 (9) | 28 (66.7) |
| -Refractory disease | 1 (1.5) | 14 (33.3) |
| Stage (Metastatic Disease) | ||
| -II | 54 (80.6) | 12 (28.6) |
| -III | 6 (9) | 6 (14.3) |
| -IV | 7 (10.4) | 24 (57.1) |
| RPLND [Post Chemotherapy] | ||
| -Yes | 32 (47.8) | 16 (38.1) |
| Necrosis/fibrosis | 11 | 5 |
| Teratoma | 20 | 8 |
| Vital carcinoma | 1 | 3 |
| -No | 35 (52.2) | 26 (61.8) |
| β-HCG Measurements | 61 (91) | 41 (98) |
| -Positive | 33 (54) | 31 (76) |
| -Negative | 28 (46) | 10 (24) |
| AFP Measurements | 62 (93) | 42 (100) |
| -Positive | 34 (55) | 27 (64) |
| -Negative | 28 (45) | 15 (36) |
| LDH Measurements | 60 (90) | 41 (98) |
| -Positive | 19 (32) | 32 (78) |
| -Negative | 41 (68) | 9 (22) |
IGCCCG: international germ cell cancer collaborative group; RPLND: retroperitoneal lymph node dissection. β-HCG (human chorionic gonadotropin), AFP (alpha-fetoprotein) and LDH (lactate dehydrogenase). $ Different histological components of non-seminoma in removed affected testicle. NED (No evidence of disease).